Srdan Verstovsek, MD, on Predicting Resistance to Hydroxyurea Therapy in Polycythemia Vera

By Leah Sherwood, Srdan Verstovsek, MD, PhD - Last Updated: December 20, 2022

Srdan Verstovsek, MD, of the MD Anderson Cancer Center, speaks on a study that used machine learning to predict resistance to hydroxyurea therapy in patients with polycythemia vera. Dr. Verstovsek and colleagues presented the study’s results at the 2022 American Society of Hematology Annual Meeting.

Post Tags:ASH22
Advertisement
Advertisement
Advertisement
Editorial Board